Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
IMA-203CD8 by Immatics for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
IMA-203CD8 is under clinical development by Immatics and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData,...
IMA-203CD8 by Immatics for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
IMA-203CD8 is under clinical development by Immatics and currently in Phase II for Squamous Non-Small Cell Lung Cancer. According to...
IMA-203CD8 by Immatics for Bladder Carcinoma: Likelihood of Approval
IMA-203CD8 is under clinical development by Immatics and currently in Phase II for Bladder Carcinoma. According to GlobalData, Phase II...
IMA-203CD8 by Immatics for Fibrosarcoma: Likelihood of Approval
IMA-203CD8 is under clinical development by Immatics and currently in Phase II for Fibrosarcoma. According to GlobalData, Phase II drugs...
IMA-203CD8 by Immatics for Thymic Carcinoma: Likelihood of Approval
IMA-203CD8 is under clinical development by Immatics and currently in Phase II for Thymic Carcinoma. According to GlobalData, Phase II...
IMA-203CD8 by Immatics for Rhabdomyosarcoma: Likelihood of Approval
IMA-203CD8 is under clinical development by Immatics and currently in Phase II for Rhabdomyosarcoma. According to GlobalData, Phase II drugs...
IMA-203CD8 by Immatics for Esophageal Cancer: Likelihood of Approval
IMA-203CD8 is under clinical development by Immatics and currently in Phase II for Esophageal Cancer. According to GlobalData, Phase II...
IMA-203CD8 by Immatics for Uterine Cancer: Likelihood of Approval
IMA-203CD8 is under clinical development by Immatics and currently in Phase II for Uterine Cancer. According to GlobalData, Phase II...
IMA-203CD8 by Immatics for Kidney Cancer (Renal Cell Cancer): Likelihood of Approval
IMA-203CD8 is under clinical development by Immatics and currently in Phase II for Kidney Cancer (Renal Cell Cancer). According to...
IMA-203CD8 by Immatics for Small-Cell Lung Cancer: Likelihood of Approval
IMA-203CD8 is under clinical development by Immatics and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData, Phase...
IMA-203CD8 by Immatics for Ovarian Cancer: Likelihood of Approval
IMA-203CD8 is under clinical development by Immatics and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase II...
IMA-203 by Immatics for Melanoma: Likelihood of Approval
IMA-203 is under clinical development by Immatics and currently in Phase II for Melanoma. According to GlobalData, Phase II drugs...
Risk adjusted net present value: What is the current valuation of Immatics's IMA-203?
IMA-203 is a gene-modified cell therapy commercialized by Immatics, with a leading Phase II program in Endometrial Cancer. According to...
IMA-203 by Immatics for Bladder Carcinoma: Likelihood of Approval
IMA-203 is under clinical development by Immatics and currently in Phase II for Bladder Carcinoma. According to GlobalData, Phase II...
IMA-203 by Immatics for Fibrosarcoma: Likelihood of Approval
IMA-203 is under clinical development by Immatics and currently in Phase II for Fibrosarcoma. According to GlobalData, Phase II drugs...
IMA-203 by Immatics for Thymic Carcinoma: Likelihood of Approval
IMA-203 is under clinical development by Immatics and currently in Phase II for Thymic Carcinoma. According to GlobalData, Phase II...
IMA-203 by Immatics for Rhabdomyosarcoma: Likelihood of Approval
IMA-203 is under clinical development by Immatics and currently in Phase II for Rhabdomyosarcoma. According to GlobalData, Phase II drugs...
IMA-203 by Immatics for Esophageal Cancer: Likelihood of Approval
IMA-203 is under clinical development by Immatics and currently in Phase II for Esophageal Cancer. According to GlobalData, Phase II...
IMA-203 by Immatics for Kidney Cancer (Renal Cell Cancer): Likelihood of Approval
IMA-203 is under clinical development by Immatics and currently in Phase II for Kidney Cancer (Renal Cell Cancer). According to...
IMA-203 by Immatics for Small-Cell Lung Cancer: Likelihood of Approval
IMA-203 is under clinical development by Immatics and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData, Phase...